Eli Lilly and Company News - October 2026
🟢 Eli Lilly is trading 8% up today after raising 2026 revenue outlook
Eli Lilly is trading at $1392.02, up 8.05%, after strong demand for Mounjaro and Zepbound drove third-quarter results. - On October 29, 2026, Eli Lilly...
Eli Lilly's third quarter 2026 revenue of $24.4B beat estimates behind surging tirzepatide demand
Eli Lilly reported a significant top- and bottom-line beat for the third quarter 2026, driven by a 53% increase in total volume primarily from its obesity and...
🟢 Eli Lilly is trading 4.38% up in pre-market after retatrutide beats Ozempic in Phase 3 trial
Eli Lilly is trading at $1,344.79, up 4.38%, after Eli Lilly reported Wednesday that its investigational retatrutide outperformed Ozempic on blood-sugar...
Eli Lilly Reports Retatrutide Beat Ozempic on Blood Sugar and Weight
Eli Lilly announced positive topline results from its TRANSCEND-T2D-2 Phase 3 trial of experimental drug retatrutide. In a head-to-head study of adults with...
Eli Lilly and Company Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
Eli Lilly is expected to report Q3 2026 revenue of $22.58 billion and an EPS of $5.38, while the current stock price of $1,273.46 remains below the $1,343.50...
🟢 Eli Lilly is trading 3.27% up today after groundbreaking at a $5 billion Virginia facility
Eli Lilly is trading 3.27% up at $1,312.29 after coverage linked the rise to its October 22, 2026, groundbreaking on a $5 billion manufacturing facility in...